COVID-19 Science & Society

How will the world look like in 2022? Is SARS-CoV-2 here to stay with us? While some countries are opening towards normal life, albeit with cautious optimism, others are experiencing the hardest disease burden and public health crisis so far. Will vaccines be effective against new variants and how long the protection will last? What do we know so far about long COVID? Which patient populations could benefit most from emerging therapeutic options? Would there be resistance to new therapies? Subscribe to the COVID-19 Science & Society podcast to find out more on the most relevant and timely topics concerning the COVID pandemic.

#10 Ravi Gupta - The Omicron Variant

Ravindra Gupta, MA, MPH, BMBCh, PhD, FRCP, FRCPath, FMedSci University of Cambridge, United Kingdom

12-08
21:04

#9 Laura Waters - Vaccines and the Immunosuppressed

Laura Waters, MD, FRCP Central & North West London NHS Foundation Trust, United Kingdom

11-25
24:47

#8 Monica Gandhi - Vaccine Schedules

Monica Gandhi, MD, MPH University of California San Francisco, United States

10-14
23:43

#7 Jean Nachega - Scaling up Vaccine Access

Jean Nachega MD, PhD, MPH, FRCP, FAAS University of Pittsburgh / Johns Hopkins University, United States Stellenbosch University, South Africa

09-30
24:22

#6 Karine Lacombe - Vaccine Safety

Karine Lacombe, MD, PhD Hôpital Saint Antoine Paris, France

09-16
23:33

#5 Michel Kazatchkine - Preparedness

Michel Kazatchkine, MD The Global Health Center, Graduate Institute for International Affairs and Development References: The Independent Panel for Pandemic Preparedness & Response

07-15
23:28

#4 Kathryn Stephenson - Variants & Vaccines

Kathryn Stephenson, MD, MPH Beth Israel Deaconess Medical Center

07-07
24:32

#3 Sanjay Bhagani - The Delta Variant

Sanjay Bhagani, BSc, FRCP Consultant Physician in Infectious Diseases/HIV Medicine and General (internal) Medicine, Royal Free Hospital

06-30
22:56

#2 Daniel Kuritzkes - Monoclonal Antibodies

Daniel Kuritzkes, MD Brigham and Women's Hospital; Harvard Medical School, United States Conflict of Interest Disclosure Receipt of grants/research support from Atea, Gilead, Merck, and ViiV Receipt of honoraria or consultation fees from Abpro, Atea, Decoy, Gilead, GlaxoSmithKline, Merck, Novartis, Rigel, ViiV

06-23
20:54

#1 Carlos del Rio - Long-term complications of COVID-19

Long-term complications of COVID-19 Carlos del Rio, MD Emory School of Medicine & Grady Health System, United States Conflict of interest disclosure Carlos del Rio has received honoraria / consultation fees from Sanofi-Pasteur References US CDC - Post-COVID Conditions https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html#:~:text=Post%2DCOVID%20conditions%20are%20a,can%20have%20post%2DCOVID%20conditions. UK Office for National Statistics - Prevalence of Ongoing Symptoms Fol...

06-11
21:50

Recommend Channels